Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
STARS CRISPR/Cas9 KO Plasmid (h): sc-406050
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- STARS CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the STARS genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: STARS Antibody (E-9): sc-393062
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
STARS CRISPR/Cas9 KO Plasmid (h) | sc-406050 | 20 µg | $397.00 |
Overview
ABRA encodes STARS (striated muscle activator of Rho signaling), an actin-binding protein enriched in cardiac and skeletal muscle that links cytoskeletal dynamics to transcriptional control. STARS promotes RhoA signaling and modulates actin-dependent regulation of SRF/MRTF-driven gene expression, integrating mechanical and contractile cues with myogenic and stress-responsive programs. Through these pathways, ABRA influences muscle differentiation, hypertrophic remodeling, and cellular responses to load and injury. Dysregulated STARS activity has been associated with cardiomyopathy- and myopathy-relevant transcriptional signatures, making ABRA a useful target for investigating cytoskeleton-to-nucleus signaling in muscle biology.
STARS CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ABRA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ABRA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ABRA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish STARS protein expression.
This CRISPR knockout system enables efficient generation of ABRA-deficient cell models for investigation of STARS signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ABRA exon(s) critical for STARS function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ABRA genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by STARS CRISPR/Cas9 KO Plasmid (h) and STARS CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ABRA locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by STARS HDR Plasmid (h) and STARS HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ABRA homology arms to support homology-directed repair at defined ABRA target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.